A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Inclusion Criteria:

• Are 18 to 80 years old (including boundary values), without limitation of sex at timeof consent.
• Based on the RECIST 1.1 criteria for disease progression, (a maximum increase intumour diameter of 20%) for participants undergoing prescreening who are receivingstandard treatment, these participants may reach the defined disease progressioncriteria at the time of tumour vaccine administration.

Exclusion Criteria:

• Have used a live attenuated vaccine within 4 weeks before the first use of SW1115C3with the following exceptions:
• Adverse reactions induced by previous anti-tumour treatments have not yet recovered toGrade ≤ 1 (except for toxicity evaluated to have no risk of safety by the PI [ordesignee], such as hair loss, Grade 2 peripheral neurotoxicity and hypothyroidismstabilised by hormone-replacement therapy) based on NCI CTCAE version 5.0.